Petrasek Danny, Bidner Marissa
California Institute of Technology (Caltech), Los Angeles, CA 90046, USA.
J Diabetes Sci Technol. 2009 May 1;3(3):533-5. doi: 10.1177/193229680900300318.
In 2008, the Action to Control Cardiovascular Risk in Diabetes trial was halted due to an unexpected number of deaths in the intensive treatment group (aiming for hemoglobin A1c levels less than 6%). Hypoglycemic episodes were thought by some to be a contributing cause, underscoring again the challenge of maintaining tight control while avoiding dangerous excursions into hypoglycemic territory. Albisser and colleagues present a set of articles in this issue of Journal of Diabetes Science and Technology that describe a clinical product developed specifically for this timeless clinical conundrum.
2008年，糖尿病心血管风险控制行动试验因强化治疗组（目标是糖化血红蛋白水平低于6%）出现意外死亡人数而提前终止。一些人认为低血糖发作是一个促成因素，这再次凸显了在维持严格控制的同时避免陷入危险的低血糖区域的挑战。阿尔比瑟及其同事在本期《糖尿病科学与技术杂志》上发表了一组文章，介绍了一种专门针对这一长期存在的临床难题开发的临床产品。
